Staged Overweight initiation at $522 captures asymmetric fundamental setup (16x P/E, $160B backlog, ~21% EPS growth) while respecting broken technical structure through ATR-calibrated sizing
The decision is to initiate Overweight with a three-tranche approach that balances directional conviction with timing discipline. The fundamental case is strong — 16x forward P/E against a $160B sole-source backlog (PAC-3, THAAD, JATM, F-35/Trident) with ~21% implied EPS growth — and historically defense primes with this contract pipeline trade at 20-22x forward. The Conservative Analyst's concerns about collection risk and contract losses are legitimate but the TTM EPS of $27.13 confirms fixed-price losses are unwinding, not permanent. The key refinement from the trader's 40% Tranche 1 proposal is the 25-30% sizing, which honors ATR-calibration lessons (~$12.86 ATR implies 7-8% expected drawdown) and avoids overcommitting into a confirmed downtrend without momentum reversal. The macro gate for Tranche 3 (10Y sub-4.75% or Fed pause) is essential discipline that separates the fundamental re-rating thesis from the multiple-compression headwind. Price target is $638 (Street consensus, ~22% upside) versus the UBS bull case of $798 if catalyst stack converts faster. Bear case to $480 if multiple compression pushes forward P/E to 14-15x. Hard stop at $458 (March/Nov 2025 swing low) provides 12% downside protection with structural invalidation on weekly close below this level.
| Position | Action |
|---|---|
| Tranche 1 entry zone $520-$525 | Deploy 25-30% of target Overweight (~0.32-0.45x benchmark weight) |
| Tranche 2 at $511 (lower Bollinger Band) or $497 (April 2026 low) | Deploy 35% of target Overweight with RSI sub-30 AND bullish divergence OR capitulation volume day confirmation |
| Tranche 3a: close above $554.65 (50 SMA) on volume ≥1.5M with MACD cross above signal line | Deploy 25% of target Overweight |
| Tranche 3b: flush to $480/$460 (Nov 2025 support zone) | Deploy 25% of target Overweight |
| Position rallies through 50 SMA on volume with macro stabilization | Trim Tranche 1 back to neutral rather than deploying Tranche 3; re-rating case weakens above ~$575 |
Technical weakness creating a generational entry point: LMT's 20% correction from ~$657 to $523.70 coincides with the largest missile-defense framework agreements in company history, a 52% upside target from UBS, and a 0.10 beta making it the cleanest defensive equity in a 5% rate environment.
| Indicator | Value | Signal |
|---|---|---|
| Close | $523.70 | neutral |
| 10 EMA | $531.71 | bearish |
| 50 SMA | $554.65 | bearish |
| 200 SMA | $555.14 | bearish |
| MACD | -8.51 | bearish |
| MACD Signal | -8.20 | bearish |
| MACD Histogram | -0.31 | bearish |
| RSI (14) | 38.84 | neutral |
| Bollinger Upper Band | $563.64 | bearish |
| Bollinger Lower Band | $511.09 | bullish |
| Bollinger Middle Band |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Contract pipeline confirms fundamental strength with multi-year production commitments accelerating: JATM air-to-air missile, tripling PAC-3 MSE, and quadrupling THAAD interceptor capacity.
↩ rebuts: “The bear's claim that the market is pricing in these awards”
EV: +52% · concedes: LMT's margin profile is lower (~12% operating margin) and growth is slower (4.4% revenue CAGR) compared to higher-beta defense names; Fixed-price contract overhang historically crushed LMT margins, though new framework agreements shift production-rate risk to government; Bear's technical recommendation to wait for $554.65 reclaim is tactically valid for pure momentum strategies, but represents chasing strength rather than buying value
LMT faces a confirmed downtrend with no reversal signals: price below all moving averages, MACD showing fresh bearish crossover, RSI not yet oversold, and multiple headwinds including fixed-price contract risk, 62% buyback reduction, 66% AR increase, and macro multiple compression pressure from 5%+ 10Y yields.
EV: -$12.61 to -$63.70 (2.4% to 12.2% downside to $511-$460) · concedes: Framework agreements are real and do provide volume certainty; Backlog of ~$160B is real and provides revenue visibility; Defensive characteristics (low beta) are real; TTM EPS trajectory does show sequential improvement; UBS analyst has a legitimate methodology even if outlier from consensus
→ vs conservative: Anchor bias on short-term technicals (below 50 SMA, negative MACD, weakening RSI) misses the point that buy zones are defined by price below moving averages; ATR compression to 12.45 and lower Bollinger quartile historically mark exhaustion, not continuation
→ vs conservative: Net income decline 27.5% reflects 2023 peak earnings normalization and fixed-price contract margin pressure already unwinding; trajectory is UP with TTM EPS $27.13 vs FY2025 $21.49
→ vs conservative: Buyback reduction of 62% is good capital discipline at depressed prices, not distress signal; free cash flow $6.9B still covers dividend 2.2x
→ vs conservative: Waiting for 50 SMA reclaim at $554 means buying 6% higher with same downside; confirmation framework surrenders $30+ of upside, reducing expected return from 22-52% to 8-12%
→ vs conservative: Macro concerns (10-year at 5%, Fed cuts at 3% probability, duration rotation) actually favor LMT as low-beta name with government-anchored earnings streams
→ vs neutral: Waiting for confirmation per the conservative framework reduces asymmetric opportunity; the trade requires asymmetric risk/reward and catalysts, both of which exist now
→ vs neutral: Beta 0.10 means moving averages are noise for a name with $160B backlog and 7-year framework agreements; institutional accumulation at $525 is the real signal
| $537.36 |
| bearish |
| ATR (14) | 12.45 | neutral |
Support: 511.09 · 497 · 480 · 460 | Resistance: 554.65 · 580 · 606
LMT exhibits a textbook bearish technical posture with price below all major moving averages, negative MACD at -8.51 with expanding histogram, and RSI at 38.84 trending toward oversold without yet reaching sub-30 extremes. The stock has corrected -20% from its February 2026 peak (~$657) and -13% just from August 14 ($602), now sitting in the lower 25% of the Bollinger envelope with immediate support at the lower band ($511.09). ATR has compressed to 12.45 from highs of 16-17, suggesting panic selling may be moderating but daily ranges of ~2.4% remain elevated. Primary resistance sits at the 50 SMA ($554.65) while critical support aligns with the lower Bollinger Band ($511.09) and April 2026 low ($497).
Market Cap
$120.87B
Current Price
~$523.70
52-Week High
$692.00
52-Week Low
$437.25
50-Day Moving Average
$557.00
200-Day Moving Average
$561.38
P/E (TTM)
19.30
Forward P/E
15.99
PEG Ratio
0.99
Price to Book
13.74
Dividend Yield
2.63%
Beta
0.104
Revenue (TTM)
$77.01B
Revenue (2025)
$75.05B
Net Income (TTM)
$6.29B
Net Income (2025)
$5.02B
EPS (TTM)
$27.13
EPS (2025)
$21.49
Forward EPS
$32.75
Operating Margin (TTM)
11.96%
Net Margin (TTM)
8.16%
Net Margin (2025)
6.68%
ROE
89.17%
ROA
8.64%
Free Cash Flow (TTM)
$5.56B
Free Cash Flow (2025)
$6.91B
Operating Cash Flow (2025)
$8.56B
CapEx (2025)
$1.65B
Total Assets (2025)
$59.84B
Total Debt (2025)
$21.70B
Net Debt (2025)
$17.58B
Stockholders Equity (2025)
$6.72B
Current Ratio
1.19
Debt/Equity
322.9%
Net Debt/EBITDA
~1.82x
Revenue CAGR (2022-2025)
4.4%
Dividends (2025)
$3.13B
Dividends (2022)
$3.02B
Buybacks (2025)
$3.0B
Buybacks (2022)
$7.9B
Accounts Receivable (2025)
$3.90B
Forward EPS Growth
~21%
Strengths
Concerns
Lockheed Martin is a high-quality aerospace & defense prime trading at a fair forward valuation (16x forward earnings, PEG 0.99) with defensive characteristics (Beta 0.10). The 2025 earnings disappointment appears to be in the rear-view mirror, with TTM metrics ($77B revenue, $27.13 EPS) materially exceeding FY2025 actuals ($75B revenue, $21.49 EPS), suggesting meaningful recovery. Capital returns are moderating but remain substantial, and FCF profile supports both buybacks and the established dividend. Principal risks include margin discipline on fixed-price contracts, customer concentration in U.S. government (70%+), and near-term technical weakness as the stock trades below key moving averages.
Macro: The dominant macro driver is the rates regime: 10-year Treasury yield hit its highest level since 2007 (~5%) and 30-year Treasury hit its highest since 2004. Prediction markets price a 97% probability of zero Fed rate cuts in 2026 (Polymarket, $8.5M traded), with 'more Fed rate hikes' discussed as a base case in Wall Street articles. U.S. recession odds are only 10%, indicating the market is not pricing a recession but rather persistent inflation and tight policy. Equity markets (Dow/S&P/Nasdaq) posted weekly losses with tech leading declines as long-duration cash flows were repriced. Oil near $100 and geopolitical uncertainty (Iran, Trump-Xi meeting) support defense demand premium. Jamie Dimon publicly stated 'it's not clear to me we've slayed inflation.' The environment is hawkish 'higher-for-longer' — favorable for relative defense outperformance but hostile for duration-rich equities and multiple expansion.